OpenAI to Acquire Orchestra Bio to Expand Drug Discovery

OpenAI announced plans to acquire Orchestra Bio to accelerate AI use in life sciences, combining Rosalind-related R&D with WorkBench to automate and speed up drug discovery. The move could directly impact corporate R&D and influence investment decisions.

Why it mattersA major move by a tech leader to advance AI in drug discovery, affecting technology strategy.